The Company is geared to meet the global challenge post implementation of TRIPS in 2005. BSV has consciously spent a substantial portion equal to approximately 7% of its turnover on R&D efforts, which materialises into non-infringing, patentable technologies for the Company. BSV has consciously developed a healthy Patent portfolio comprising of seven International Patents. These International Patents are in various stages of examination and registration and filing in various countries.

BSV's ability to create Intellectual Property portfolio lies in its research team and its infrastructure, which have the ability to take an initial idea from the basic development through pre-clinical studies, clinical trials, and regulatory clearances to the commercialization of the product. Due to in-house capabilities to perform the various research activities, reduced efforts and cost savings are possible. The Company's business strategy is designed to provide a continuing pipeline of proprietary new generation therapeutic products and approaches through ongoing research programmes as well as through collaborative research programmes.